Journal of Chemotherapy最新文献_第2页

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-01-07 DOI: 10.1080/1120009X.2024.2448644

Omar Elghawy, Reema Patel, Abhishek Mullapudi, Martin Kurian, John Wang, Jessica Xu, Varinder Kaur

{"title":"Immune-related adverse events not associated with survival in advanced or metastatic gastroesophageal cancers.","authors":"Omar Elghawy, Reema Patel, Abhishek Mullapudi, Martin Kurian, John Wang, Jessica Xu, Varinder Kaur","doi":"10.1080/1120009X.2024.2448644","DOIUrl":"https://doi.org/10.1080/1120009X.2024.2448644","url":null,"abstract":"Immune checkpoint inhibitors (ICIs) have shown promise in the treatment of gastric and oesophageal cancers (GEC). Despite their promising efficacy, ICIs have been associated with unique side effects known as immune-related adverse events (IRAEs). Several studies have shown improved treatment responses in patients with IRAEs compared to those without IRAEs in various cancer types such as melanoma and non-small cell lung cancer. We performed a single-institution retrospective study to characterize IRAE incidence and association with treatment response in advanced GEC. We identified 70 patients with GEC who received ICI therapy; 20 (29%) developed an IRAE of any magnitude. The most common were colitis (35%) hypothyroidism (25%) and pneumonitis (20%). Median PFS and OS were not statistically different between IRAE and nonIRAE groups (10.4 vs. 11.3 months p = 0.6 and 11.0 vs. 12.9 months p = 1.0, respectively). This is in contrast to studies in other cancer types that have suggested association between IRAE and improved outcomes.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-7"},"PeriodicalIF":1.9,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142948424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An acquired CCDC6::RET gene fusion as resistance mechanism for Osimertinib in exon 21 EGFR(L858R)-mutated non-small cell lung cancer and its successful management with Osimertinib and Selpercatinib: a case report and review of literature. 在21外显子EGFR（L858R）突变的非小细胞肺癌中，获得性CCDC6::RET基因融合作为奥西替尼耐药机制，以及奥西替尼和塞尔珀卡替尼的成功治疗：一例报告和文献综述。

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-01-05 DOI: 10.1080/1120009X.2024.2445909

Maud Lormans, Peter Van Haecke, Ingel Demedts

{"title":"An acquired CCDC6::RET gene fusion as resistance mechanism for Osimertinib in exon 21 EGFR(L858R)-mutated non-small cell lung cancer and its successful management with Osimertinib and Selpercatinib: a case report and review of literature.","authors":"Maud Lormans, Peter Van Haecke, Ingel Demedts","doi":"10.1080/1120009X.2024.2445909","DOIUrl":"https://doi.org/10.1080/1120009X.2024.2445909","url":null,"abstract":"Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) are the recommended front-line therapy for treatment-naïve patients with advanced stage EGFR mutated Non-Small Cell Lung Cancer (NSCLC), with better tolerance and outcomes compared to chemotherapy. However, patients inevitably develop resistance to EGFR-TKI. The extent of progression free survival depends on intrinsic or acquired on-target/off-target mechanisms of EGFR-TKI resistance. Overcoming these acquired rearrangements remains challenging in modern precision medicine. In case of disease progression during treatment with an EGFR-TKI, rebiopsy is recommended to search for a potential resistance mechanism. However, the therapeutic potential of these resistance mechanisms represents an unmet need in thoracic oncology. CasePresentation: We present a case of a 78-year-old woman with stage IVB EGFR-mutated NSCLC in whom an acquired RET Gene Fusion was identified as the EGFR-independent resistance mechanism. Additionally, a combined therapy of Osimertinib and Selpercatinib showed a durable oncological response with 14 months of progression free survival in the absence of adverse events. Conclusion: Addition of Selpercatinib to Osimertinib in an EGFR-mutated NSCLC patient with an acquired RET fusion was well tolerated and created a clinical benefit. Further prospective investigation into these novel combination strategies is needed as resistance mechanisms could serve as possible targets for new therapy approaches.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-6"},"PeriodicalIF":1.9,"publicationDate":"2025-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessment of in vitro interactions between delafloxacin and other antimicrobials against multi-drug resistant Pseudomonas aeruginosa strains. 德拉沙星与其他抗多重耐药铜绿假单胞菌菌株的体外相互作用评价。

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2024-12-26 DOI: 10.1080/1120009X.2024.2445910

Emel Mataracı Kara, Selin Melis Çakmak, Sevda Er

{"title":"Assessment of in vitro interactions between delafloxacin and other antimicrobials against multi-drug resistant Pseudomonas aeruginosa strains.","authors":"Emel Mataracı Kara, Selin Melis Çakmak, Sevda Er","doi":"10.1080/1120009X.2024.2445910","DOIUrl":"https://doi.org/10.1080/1120009X.2024.2445910","url":null,"abstract":"Novel therapeutic interventions are required to address the critical antimicrobial resistance caused by multidrug-resistant Pseudomonas aeruginosa (MDR-PA) infections. This study examines the impact of combining delafloxacin with antibiotics on MDR-PA isolated from various samples. The minimum inhibitory concentrations (MICs) of delafloxacin, alone and in combination with other antibiotics, were determined against forty distinct MDR-PA isolates using the broth microdilution method. Time-kill curve assays were used to determine the bactericidal and synergistic effects of delafloxacin alone and in combination with other antibiotics in vitro against the selected five strains. Our studies showed delafloxacin exhibited four times greater in-vitro activity against MDR-PA strains than levofloxacin compared with both MIC50 and MIC90 results. Delafloxacin + tobramycin and delafloxacin + ceftazidime/avibactam showed synergy in two out of five strains tested at concentrations equal to the MIC. The outcomes of this research also suggest that these combinations may replace therapy for MDR-PA strains.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-7"},"PeriodicalIF":1.9,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Physiological markers for immunotherapeutics: a review. 免疫治疗生理学标志物研究进展。

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2024-12-22 DOI: 10.1080/1120009X.2024.2443701

Durlav Chowdhury, Ashmita Das, Mrityunjay Mishra, Trinkal Khutere, Surendra H Bodakhe

引用次数: 0

Optimizing the dosing regimens of linezolid against gram-positive cocci in critically ill patients with different renal functions: a Monte Carlo simulation. 不同肾功能重症患者利奈唑胺抗革兰阳性球菌给药方案的优化：蒙特卡罗模拟。

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2024-12-13 DOI: 10.1080/1120009X.2024.2440192

Hongyu Qiu, Hao Li, Lingti Kong

引用次数: 0

Therapy-related hand-foot syndrome: a review. 治疗相关手足综合征：综述。

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2024-12-09 DOI: 10.1080/1120009X.2024.2437336

Bilha Baby, Nevin Sam, Narmadha M P, Gopikrishnan Anjaneyan, Rakesh M P

引用次数: 0

The acceleration of cisplatin resistance in colorectal cancer by lncRNA NORAD through regulation of miR-106a-5p/Cyclin D1 axis. lncRNA NORAD通过调控miR-106a-5p/Cyclin D1轴加速结直肠癌顺铂耐药

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2024-12-08 DOI: 10.1080/1120009X.2024.2436808

Liping Guo, Xianmei Li, Yujuan Kang, Hui Sun

{"title":"The acceleration of cisplatin resistance in colorectal cancer by lncRNA NORAD through regulation of miR-106a-5p/Cyclin D1 axis.","authors":"Liping Guo, Xianmei Li, Yujuan Kang, Hui Sun","doi":"10.1080/1120009X.2024.2436808","DOIUrl":"https://doi.org/10.1080/1120009X.2024.2436808","url":null,"abstract":"Colorectal cancer (CRC) is one of the leading causes of cancer-related mortality. LncRNA NORAD is frequently upregulated and positively associated with various cancer progressions. We discovered NORAD was significantly upregulated in CRC tissues and cells. NORAD sponged miR-106a-5p to form a ceRNA complex. MiR-106a-5p was remarkedly downregulated in CRC tumors and cells. Silencing NORAD or overexpression of miR-106a-5p effectively increased cisplatin sensitivity. In the established cisplatin resistant cell line, NORAD was upregulated and miR-106a-5p was downregulated. Furthermore, we disclosed miR-106a-5p directly targeted 3'UTR of CCND1, which is an important cell cycle regulator and is frequently overexpressed in human cancers. Rescue experiments showed restoration of CCND1 in miR-106a-5p-overexpressing CRC cells successfully recovered cisplatin resistance. Finally, restoration of miR-106a-5p in NORAD-overexpressing CRC cells re-sensitized cisplatin resistance by targeting CCND1. Summarily, this study uncovered a NORAD-promoted cisplatin resistance through modulating the miR-106a-5p-CCND1 axis, contributing to developing novel therapy for treating chemoresistant CRC.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-12"},"PeriodicalIF":1.9,"publicationDate":"2024-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

LncRNA-FGD5-AS1 promotes 5-Fu resistance of cervical cancer cells through modulating the miR-130a-3p-YTHDF2 axis. LncRNA-FGD5-AS1通过调节miR-130a-3p-YTHDF2轴促进宫颈癌细胞对5-Fu的抗性。

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2024-12-06 DOI: 10.1080/1120009X.2024.2436803

Zhiyong Xia, Liping Zhang, Honggui Zhou, Wei Ran, Jihong Tu

{"title":"LncRNA-FGD5-AS1 promotes 5-Fu resistance of cervical cancer cells through modulating the miR-130a-3p-YTHDF2 axis.","authors":"Zhiyong Xia, Liping Zhang, Honggui Zhou, Wei Ran, Jihong Tu","doi":"10.1080/1120009X.2024.2436803","DOIUrl":"https://doi.org/10.1080/1120009X.2024.2436803","url":null,"abstract":"Cervical cancer is one of the most common gynecologic malignancies worldwide. 5-Fluorouracil (5-Fu) is a widely used anticancer drug for various cancers, but the development of 5-Fu resistance poses a challenge in treating cervical cancer patients. This study examined the roles and molecular mechanisms of LncRNA-FGD5-AS1 in 5-Fu resistant cervical cancer cells through in vitro and in vivo experiments. We discovered FGD5-AS1 and the RNA methylation reader protein, YTHDF2, were positively associated with 5-Fu resistance in cervical cancer. A positive correlation between FGD5-AS1 and YTHDF2 was found in cervical tumor tissues. Expressions of FGD5-AS1 and YTHDF2 were significantly upregulated in the established 5-Fu resistant cervical cancer cells. MiRNA-microArray analysis screened that FGD5-AS1 downregulated miR-130a-3p expression in cervical cancer cells. Subsequently, we demonstrated FGD5-AS1 acted as a ceRNA by sponging miR-130a-3p, which targeted the 3'UTR of YTHDF2 mRNA. Rescue experiments validated overexpression of FGD5-AS1 increased 5-Fu resistance in cervical cancer cells, which was reversed by miR-130a-3p overexpression. Finally, combining FGD5-AS1 silencing with 5-Fu treatments resulted in a synergistic inhibitory effect (CI < 1) on the viability of cervical cancer cells. This study reveals a FGD5-AS1-miR-130a-3p-YTHDF2 axis that could be a promising therapeutic target for overcoming 5-Fu resistance in cervical cancer.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-13"},"PeriodicalIF":1.9,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical benefit of anti-PD-1/PD-L1 plus chemotherapy in first-line treatment for patients over the age of 65 or 75 with metastatic non-small cell lung cancer (NSCLC). 抗PD-1/PD-L1联合化疗对65岁或75岁以上转移性非小细胞肺癌（NSCLC）患者一线治疗的临床疗效。

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2024-12-01 Epub Date: 2024-02-01 DOI: 10.1080/1120009X.2024.2308978

Thierry Landre, Christos Chouaïd, Nassyma Sadaoui, Djamila Bouharati, Chérifa Taleb

{"title":"Clinical benefit of anti-PD-1/PD-L1 plus chemotherapy in first-line treatment for patients over the age of 65 or 75 with metastatic non-small cell lung cancer (NSCLC).","authors":"Thierry Landre, Christos Chouaïd, Nassyma Sadaoui, Djamila Bouharati, Chérifa Taleb","doi":"10.1080/1120009X.2024.2308978","DOIUrl":"10.1080/1120009X.2024.2308978","url":null,"abstract":"Anti-PD-1/PD-L1 plus chemotherapy (CT) is considered the standard of care in first line treatment of metastatic NSCLC. However, the clinical benefit of this combination in older patients is controversial. We performed a meta-analysis of phase III randomized trials that compared PD-1/PD-L1 inhibitor plus CT with CT alone in first line of treatment for older patients with advanced NSCLC. Subgroups of patients over 65 and over 75 were analyzed. The outcomes included overall survival (OS) and progression-free survival (PFS). A fixedeffect model was used. We analyzed ten trials with an anti-PD-1 (camrelizumab, cemiplimab, nivolumab, pembrolizumab, tislelizumab or toripalimab) and six trials with an anti-PD-L1 (atezolizumab, durvalumab or sugemalimab), including 3666 patients over the age of 65 (41%) and 282 patients over the age of 75 (<10%). For patients over 65 years of age, anti-PD- 1/PD-L1 + CT was significantly associated (hazard ratio [95% confidence interval]) with prolonged OS (0.79 [0.72-0.86]; p < 0.00001) and P FS (0.63 [0.58-0.68]; p < 0.00001) compared to CT alone. Survival benefits occurred in both anti-PD-1 and anti-PD-L1 trials. For patients over 75 years of age, OS benefit was not statistically significant (0.88 [0.67-1.16]; p = 0.37). For patients over the age of 65 with untreated NSCLC, the anti-PD-1/PD-L1 combination with CT, compared with CT alone, is associated with significantly improved OS and PFS. Due to the low number of patients, it is difficult to conclude for those over 75.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"675-681"},"PeriodicalIF":1.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139671905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mechanisms underlying dose-limiting toxicities of conventional chemotherapeutic agents. 传统化疗药物剂量限制性毒性的机制。

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2024-12-01 Epub Date: 2024-01-05 DOI: 10.1080/1120009X.2023.2300217

Mohammad Amin Manavi, Mohammad Hosein Fathian Nasab, Razieh Mohammad Jafari, Ahmad Reza Dehpour

{"title":"Mechanisms underlying dose-limiting toxicities of conventional chemotherapeutic agents.","authors":"Mohammad Amin Manavi, Mohammad Hosein Fathian Nasab, Razieh Mohammad Jafari, Ahmad Reza Dehpour","doi":"10.1080/1120009X.2023.2300217","DOIUrl":"10.1080/1120009X.2023.2300217","url":null,"abstract":"Dose-limiting toxicities (DLTs) are severe adverse effects that define the maximum tolerated dose of a cancer drug. In addition to the specific mechanisms of each drug, common contributing factors include inflammation, apoptosis, ion imbalances, and tissue-specific enzyme deficiencies. Among various DLTs are bleomycin-induced pulmonary fibrosis, doxorubicin-induced cardiomyopathy, cisplatin-induced nephrotoxicity, methotrexate-induced hepatotoxicity, vincristine-induced neurotoxicity, paclitaxel-induced peripheral neuropathy, and irinotecan, which elicits severe diarrhea. Currently, specific treatments beyond dose reduction are lacking for most toxicities. Further research on cellular and molecular pathways is imperative to improve their management. This review synthesizes preclinical and clinical data on the pharmacological mechanisms underlying DLTs and explores possible treatment approaches. A comprehensive perspective reveals knowledge gaps and emphasizes the need for future studies to develop more targeted strategies for mitigating these dose-dependent adverse effects. This could allow the safer administration of fully efficacious doses to maximize patient survival.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"623-653"},"PeriodicalIF":1.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139097890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0